Douglas A. Keller

ORCID: 0000-0002-6186-2881
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Carcinogens and Genotoxicity Assessment
  • Sulfur Compounds in Biology
  • Computational Drug Discovery Methods
  • Animal testing and alternatives
  • 3D Printing in Biomedical Research
  • Pharmacogenetics and Drug Metabolism
  • Effects and risks of endocrine disrupting chemicals
  • Genomics, phytochemicals, and oxidative stress
  • Molecular Biology Techniques and Applications
  • Pesticide Exposure and Toxicity
  • Fish biology, ecology, and behavior
  • Pluripotent Stem Cells Research
  • Fluorine in Organic Chemistry
  • Folate and B Vitamins Research
  • Physiological and biochemical adaptations
  • Per- and polyfluoroalkyl substances research
  • Immunotoxicology and immune responses
  • Cancer, Hypoxia, and Metabolism
  • Glutathione Transferases and Polymorphisms
  • Health Systems, Economic Evaluations, Quality of Life
  • Drug Transport and Resistance Mechanisms
  • Analytical Chemistry and Chromatography
  • PI3K/AKT/mTOR signaling in cancer
  • Water Treatment and Disinfection
  • Bone and Dental Protein Studies

Sanofi (United States)
2002-2020

Bridgewater College
2020

Sanofi (France)
2001-2019

Statistisches Bundesamt
2018

Mercer Island School District
2016

Research Triangle Park Foundation
1988-2015

Universität Hamburg
2015

University Medical Center Hamburg-Eppendorf
2015

Incyte (United States)
2010

Experimental Station
2010

Data collected from 182 marketed and nonmarketed pharmaceuticals demonstrate that there is little value gained in conducting a rat two-year carcinogenicity study for compounds lack: (1) histopathologic risk factors neoplasia chronic toxicology studies, (2) evidence of hormonal perturbation, (3) positive genetic results. Using single result among these three criteria as test outcome the study, fifty-two sixty-six tumorigens were correctly identified, yielding 79% sensitivity. When all...

10.1177/0192623311406935 article EN Toxicologic Pathology 2011-06-01

FutureTox II, a Society of Toxicology Contemporary Concepts in workshop, was held January, 2014. The meeting goals were to review and discuss the state science toxicology context implementing NRC 21st century vision predicting vivo responses from vitro silico data, define for future. Presentations discussions on priority concerns such as modeling metabolism, cell growth differentiation, effects sensitive subpopulations, integrating data into risk assessment. Emerging trends technologies stem...

10.1093/toxsci/kfu234 article EN Toxicological Sciences 2015-01-24

The practice of toxicology is changing rapidly, as demonstrated by the response to 2007 NRC report on "Toxicity Testing in 21st Century." New assays are being developed replace animal testing; yet use data from these decision making not clear. A Health and Environmental Sciences Institute committee held a May 2011 workshop discuss approaches identifying adverse effects context report. Scientists industry, government, academia, NGOs discussed two case studies explored how information new,...

10.1093/toxsci/kfr350 article EN Toxicological Sciences 2012-01-19

Tissue chips are poised to deliver a paradigm shift in drug discovery. By emulating human physiology, these have the potential increase predictive power of preclinical modeling, which turn will move pharmaceutical industry closer its aspiration clinically relevant and ultimately animal-free Despite tremendous science innovation invested tissue chips, significant challenges remain be addressed enable their routine adoption into industrial laboratory. This article describes main steps that...

10.1177/1535370217715441 article EN Experimental Biology and Medicine 2017-06-16

The ICH S1B carcinogenicity global testing guideline has been recently revised with a novel addendum that describes comprehensive integrated Weight of Evidence (WoE) approach to determine the need for 2-year rat study. In present work, experts from different organizations have joined efforts standardize as much possible procedural framework integration evidence associated S1B(R1) WoE criteria. uses pragmatic consensus procedure hazard assessment facilitate transparent, consistent, and...

10.3389/ftox.2024.1370045 article EN cc-by Frontiers in Toxicology 2024-04-05

10.1016/0006-291x(83)90842-2 article EN Biochemical and Biophysical Research Communications 1983-07-01

The aminoacylase that catalyzes the hydrolysis of N-acetyl-l-cysteine (NAC) was identified as acylase I after purification by column chromatography and electrophoretic analysis. Rat kidney cytosol fractionated ammonium sulfate precipitation, proteins were separated ion-exchange chromatography, gel-filtration hydrophobic interaction chromatography. Acylase activity with NAC N-acetyl-l-methionine (NAM), a known substrate for I, substrates coeluted during all chromatographic steps. Sodium...

10.1021/tx980018b article EN Chemical Research in Toxicology 1998-06-19

Future Tox III, a Society of Toxicology Contemporary Concepts in workshop, was held November 2015. Building upon I and II, III focused on developing the high throughput risk assessment paradigm taking science vitro data silico models forward to explore question—what progress is being made address challenges implementing emerging big-data toolbox for regulatory decision-making. This article reports outcome workshop including 2 examples where advancements predictive toxicology approaches are...

10.1093/toxsci/kfw194 article EN Toxicological Sciences 2016-10-25

To identify a CCR5 antagonist as an HIV-1 entry inhibitor, we designed novel series of indane derivatives based on conformational considerations. Modification the ring led to discovery compound 22a (INCB9471) that exhibited high affinity for CCR5, potent anti-HIV-1 activity, receptor selectivity, excellent oral bioavailability, and tolerated safety profile. INCB9471 has entered human clinical trials.

10.1021/ml1001536 article EN ACS Medicinal Chemistry Letters 2010-08-25

An Innovation and Quality (IQ) Consortium focus group conducted a cross-company survey to evaluate current practices perceptions around the use of animal models disease (AMDs) in nonclinical safety assessment molecules clinical development. The IQ is an organization pharmaceutical biotechnology companies with mission advancing science technology. queried utilization AMDs during drug discovery which candidates are evaluated efficacy limited short-duration non-Good Laboratory Practices (GLP)...

10.1177/0192623317701004 article EN Toxicologic Pathology 2017-03-28

Base treatment of polyethylene glycol-derivatized superoxide dismutase in which the glycol is linked to protein via a succinyl bridge, removes leaving marker. Exhaustive succinylation with d4-succinic anhydride completes derivatization order minimize fractionation proteolysis, chromatography, and desorption mass spectrometer. Production peptides from derivatized for high resolution high-resolution tandem MS allows identification site that had been by determination amount originally at each...

10.1016/s0090-9556(25)08181-4 article EN Drug Metabolism and Disposition 1993-09-01

10.1007/978-1-4684-5134-4_46 article EN Advances in experimental medicine and biology 1986-01-01
Coming Soon ...